Biotechnology 24 May 2026 - 28 May 2026

Aura Biosciences Stock Falls After Eye-Cancer Trial News
····

Aura Biosciences Stock Falls After Eye-Cancer Trial News

Aura Biosciences shares fell 4.2% to $6.89 Tuesday after the company announced it completed enrollment of 108 patients in its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma. Topline results are expected in the second half of 2027. The company reported $114.7 million in cash at the end of March and raised $280.8 million more in a recent equity sale. Aura has no approved products and relies on bel-sar for future growth.
June 2, 2026
Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug
····

Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug

Maze Therapeutics shares slipped 1.2% to $26.05 in early Nasdaq trading Thursday, valuing the company near $1.4 billion. CEO Jason Coloma will present at Jefferies and Goldman Sachs healthcare conferences in June, where investors expect updates on the MZE829 kidney drug program. Maze reported $528 million in cash after an April stock sale and aims to start another Phase 2 study mid-year.
May 28, 2026
DNA X Stock Looks at Nasdaq Deadline After Latest Financing
····

DNA X Stock Looks at Nasdaq Deadline After Latest Financing

DNA X said Nasdaq will delist its shares after the company fell short of stockholders’ equity rules, posting a $983,000 deficit for the March quarter. The company plans to request a hearing by May 29 to halt suspension as it appeals. DNA X shares last traded at $4.07 in premarket, valuing the firm at about $5.1 million. The company also announced a $3.05 million convertible note financing.
May 28, 2026
BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle
····

BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle

BioNexus Gene Lab Corp. rose 1.45% to $2.10 in light Nasdaq trading Wednesday, with under 3,000 shares changing hands. First-quarter revenue dropped to $22,842 from $2.14 million a year ago, mainly due to weaker Chemrex results. The company is seeking to recover $2.94 million from former Chemrex officers over disputed payments. BioNexus warned of “substantial doubt” about its ability to continue as a going concern.
May 27, 2026
Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window
····

Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window

Voyager Therapeutics shares rose 4 cents to $3.83 in thin premarket trading, valuing the company at $228 million. H.C. Wainwright reiterated a Buy rating and $25 target, citing upcoming milestones including first human dosing for VY1706 and tau PET imaging data for VY7523 in the second half of 2026. Voyager reported $171.7 million in cash at the end of Q1.
May 27, 2026
Zenas BioPharma Stock Slips as a June Catalyst Moves Into View
····

Zenas BioPharma Stock Slips as a June Catalyst Moves Into View

Zenas BioPharma shares fell 1.3% to $18.73 on Tuesday, underperforming the biotech sector ahead of a June 4 presentation of Phase 3 data for its autoimmune drug obexelimab. The trial showed a 56% reduction in IgG4-RD flare risk, below Amgen’s Uplizna, which cut risk by 87%. Zenas plans to seek FDA approval this quarter. Investors remain cautious as the stock trades well below its 52-week high.
May 27, 2026
RF Acquisition II Shares Steady as $1.5 Billion AI-Biotech SPAC Deal Draws Attention Again
·····

RF Acquisition II Shares Steady as $1.5 Billion AI-Biotech SPAC Deal Draws Attention Again

RF Acquisition Corp II shares closed at $10.97 in light trading Tuesday after Nasdaq reopened post-Memorial Day. The SPAC’s stock hovered near its $10.95 redemption value as it faces a tight deadline to complete its planned merger with Nanyang Biologics. RFAI reported $52.9 million in its trust account as of March 31 and warned of “substantial doubt” about its ability to continue if a deal is not completed.
May 27, 2026
Indaptus Therapeutics Drops on Cash Runway Worries
····

Indaptus Therapeutics Drops on Cash Runway Worries

Indaptus Therapeutics shares fell 6.6% to $1.14 Tuesday after the company reported $1.5 million in cash at March 31 and raised “substantial doubt” about its ability to continue operating. The company stopped enrolling patients in its main clinical trial and has no approved therapies or product revenue. Indaptus converted all Series AA and AAA preferred shares into 111 million common shares during the quarter.
May 26, 2026
Standard BioTools shares hold over $1 as Nasdaq deadline nears
····

Standard BioTools shares hold over $1 as Nasdaq deadline nears

Standard BioTools shares rose 4.4% to $1.075 early Tuesday, trading above Nasdaq’s $1 minimum bid but still short of the required compliance streak. Volume reached about 1.19 million shares. The company reported Q1 revenue of $21.1 million, up 5%, with lower costs but weak instrument demand. Standard BioTools has until Oct. 19 to regain full compliance with Nasdaq rules.
May 26, 2026
BridgeBio shares slip as 2031 drug pricing risk pops up
····

BridgeBio shares slip as 2031 drug pricing risk pops up

BridgeBio Pharma shares fell 2.8% to $67.18 after Raymond James downgraded the stock, citing payer-driven risks for its heart drug Attruby. The downgrade follows concerns that insurers may favor cheaper generics as Pfizer’s Vyndamax nears loss of exclusivity in 2031. BridgeBio reported $194.5 million in Q1 revenue, mostly from Attruby, and approved a $500 million buyback. The stock lagged biotech sector gains Tuesday.
May 26, 2026
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch
····

Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch

Senti Biosciences shares traded near $1 in U.S. premarket Tuesday after the Memorial Day break, following an FDA update on its SENTI-202 cell therapy. The company reported $8.9 million in cash at March 31 and a $4.2 million quarterly net loss. Senti secured a financing deal for up to $40 million in convertible notes with Celadon Partners. The biotech sector remained weak ahead of the holiday.
May 26, 2026
Harvard Bioscience: HBIO stock stalls, margin pressure in focus
····

Harvard Bioscience: HBIO stock stalls, margin pressure in focus

Harvard Bioscience closed at $5.59 Friday, up 1.3% for the day and 6.5% for the week, following a 1-for-10 reverse stock split in March. First-quarter revenue fell to $20.8 million, with a net loss of $3.4 million and gross margin rising to 59%. The company cited weak demand from academic and distributor customers and faces a 17.3% effective interest rate on borrowings. CEO John Duke and CFO Mark Frost will speak at a virtual conference May 28.
May 25, 2026
Molecular Partners Stock Pops Into Holiday Pause as Traders Eye Cancer-Drug Data
····

Molecular Partners Stock Pops Into Holiday Pause as Traders Eye Cancer-Drug Data

Molecular Partners shares closed at CHF 3.15 on Friday, up 9.38%, ahead of a market pause for Whit Monday and Memorial Day. The company will present first-in-human data for its lead Radio-DARPin candidate MP0712 at a Basel meeting on May 29. Q1 filings showed no revenue, R&D costs of CHF 9.45 million, and a net loss of CHF 13.14 million. Cash reserves stood at CHF 79 million at March-end.
May 25, 2026
Crinetics Stock Trades Flat Ahead of June Investor Event
····

Crinetics Stock Trades Flat Ahead of June Investor Event

CRNX closed Friday at $36.80, nearly flat for the week, with a market cap near $3.83 billion. Crinetics will attend the Jefferies Global Healthcare Conference in New York on June 2-4. U.S. stock markets are closed Monday for Memorial Day. The company reported first-quarter revenue of $10.7 million, driven by its Palsonify launch, but posted a net loss of $127.8 million.
May 25, 2026
ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data
····

ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data

ProQR shares closed at $1.56 on May 22, up 8.3%, then slipped to $1.54 after hours, finishing the week down 1.9%. The company expects AX-0810 target-engagement data in Q2 and has prioritized biliary atresia for its next development step. ProQR ended March with €81.1 million in cash, enough to fund operations into mid-2027. The annual meeting is set for June 2 in Amsterdam.
May 24, 2026
GeneDx Shares Watch After Holder Filings in Holiday Week
····

GeneDx Shares Watch After Holder Filings in Holiday Week

GeneDx shares closed at $47.31 Friday, up 16% from last week but still 30% below early May levels after a post-earnings drop. SEC filings show Eli Casdin and Keith Meister now hold 13.7% and 17.9% stakes, respectively, after recent open-market purchases. The company cut 2026 revenue guidance and reported Q1 revenue of $102.3 million, missing expectations by $12 million. U.S. markets reopen Tuesday after Memorial Day.
May 24, 2026
Lunai Bioworks Heads Into Key Week After Reverse Split, Ongoing Court Battle
····

Lunai Bioworks Heads Into Key Week After Reverse Split, Ongoing Court Battle

Lunai Bioworks closed at $2.26 Friday, down 2.62%, after a 1-for-8 reverse split aimed at regaining Nasdaq compliance. A Delaware magistrate judge granted Lunai expedited discovery over alleged naked short selling. Nasdaq will remain closed Monday for Memorial Day. Lunai continues to face listing deadlines and reported a $2.57 million net loss for the March quarter.
May 24, 2026
1 2 3 4 5